|
1
|
Ostrom QT, Gittleman H, Farah P, Ondracek
A, Chen Y, Wolinsky Y, Stroup NE, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: primary brain and central nervous system
tumors diagnosed in the United States in 2006–2010. Neuro Oncol. 15
Sup 6:ii1–ii56. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: European Organisation for Research and Treatment of
Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N Engl J
Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Delgado-López PD and Corrales-García EM:
Survival in glioblastoma: A review on the impact of treatment
modalities. Clin Transl Oncol. 18:1062–1071. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weller M, van den Bent M, Hopkins K, Tonn
JC, Stupp R, Falini A, Cohen-Jonathan-Moyal E, Frappaz D,
Henriksson R, Balana C, et al: European Association for
Neuro-Oncology (EANO) Task Force on Malignant Glioma: EANO
guideline for the diagnosis and treatment of anaplastic gliomas and
glioblastoma. Lancet Oncol. 15:e395–e403. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Montemurro N, Perrini P, Blanco MO and
Vannozzi R: Second surgery for recurrent glioblastoma: A concise
overview of the current literature. Clin Neurol Neurosurg.
142:60–64. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tosoni A, Franceschi E, Poggi R and
Brandes AA: Relapsed Glioblastoma: Treatment Strategies for Initial
and Subsequent Recurrences. Curr Treat Options Oncol. 17:492016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hervey-Jumper SL and Berger MS:
Reoperation for recurrent high-grade glioma: A current perspective
of the literature. Neurosurgery. 75:491–499; discussion 498–499.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Davis ME: Glioblastoma: Overview of
Disease and Treatment. Clin J Oncol Nurs. 20:S2–S8. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Brandes AA, Bartolotti M, Tosoni A, Poggi
R, Bartolini S, Paccapelo A, Bacci A, Ghimenton C, Pession A,
Bortolotti C, et al: Patient outcomes following second surgery for
recurrent glioblastoma. Future Oncol. 12:1039–1044. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suchorska B, Weller M, Tabatabai G, Senft
C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C,
et al: Complete resection of contrast-enhancing tumor volume is
associated with improved survival in recurrent glioblastoma-results
from the DIRECTOR trial. Neuro-oncol. 18:549–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gorlia T, Stupp R, Brandes AA, Rampling
RR, Fumoleau P, Dittrich C, Campone MM, Twelves CC, Raymond E, Hegi
ME, et al: New prognostic factors and calculators for outcome
prediction in patients with recurrent glioblastoma: A pooled
analysis of EORTC Brain Tumour Group phase I and II clinical
trials. Eur J Cancer. 48:1176–1184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nava F, Tramacere I, Fittipaldo A,
Bruzzone MG, Dimeco F, Fariselli L, Finocchiaro G, Pollo B,
Salmaggi A, Silvani A, et al: Survival effect of first- and
second-line treatments for patients with primary glioblastoma: A
cohort study from a prospective registry, 1997–2010. Neuro-oncol.
16:719–727. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Taunk NK, Moraes FY, Escorcia FE, Mendez
LC, Beal K and Marta GN: External beam re-irradiation, combination
chemoradiotherapy, and particle therapy for the treatment of
recurrent glioblastoma. Expert Rev Anticancer Ther. 16:347–358.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sulman EP, Ismaila N, Armstrong TS, Tsien
C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely
M, et al: Radiation Therapy for Glioblastoma: American Society of
Clinical Oncology Clinical Practice Guideline Endorsement of the
American Society for Radiation Oncology Guideline. J Clin Oncol.
35:361–369. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mizumoto M, Yamamoto T, Ishikawa E,
Matsuda M, Takano S, Ishikawa H, Okumura T, Sakurai H, Matsumura A
and Tsuboi K: Proton beam therapy with concurrent chemotherapy for
glioblastoma multiforme: Comparison of nimustine hydrochloride and
temozolomide. J Neurooncol. 130:165–170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Minniti G, Armosini V, Salvati M, Lanzetta
G, Caporello P, Mei M, Osti MF and Maurizi RE: Fractionated
stereotactic reirradiation and concurrent temozolomide in patients
with recurrent glioblastoma. J Neurooncol. 103:683–691. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adeberg S, Harrabi SB, Bougatf N,
Bernhardt D, Rieber J, Koerber SA, Syed M, Sprave T, Mohr A,
Abdollahi A, et al: Intensity-modulated proton therapy,
volumetric-modulated arc therapy, and 3D conformal radiotherapy in
anaplastic astrocytoma and glioblastoma: A dosimetric comparison.
Strahlenther Onkol. 192:770–779. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Matsuda M, Yamamoto T, Ishikawa E, Nakai
K, Zaboronok A, Takano S and Matsumura A: Prognostic factors in
glioblastoma multiforme patients receiving high-dose particle
radiotherapy or conventional radiotherapy. Br J Radiol. 84:S54–S60.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mizumoto M, Okumura T, Ishikawa E,
Yamamoto T, Takano S, Matsumura A, Oshiro Y, Ishikawa H, Sakurai H
and Tsuboi K: Reirradiation for recurrent malignant brain tumor
with radiotherapy or proton beam therapy. Technical considerations
based on experience at a single institution. Strahlenther Onkol.
189:656–663. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Galle JO, McDonald MW, Simoneaux V and
Buchsbaum JC: Reirradiation with proton therapy for recurrent
gliomas. Int J Part Ther. 2:11–18. 2015. View Article : Google Scholar
|
|
21
|
Seystahl K, Wick W and Weller M:
Therapeutic options in recurrent glioblastoma-An update. Crit Rev
Oncol Hematol. 99:389–408. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Xing D, Zhao M, Wang J and Yang Y:
The role of a single angiogenesis inhibitor in the treatment of
recurrent glioblastoma multiforme: A meta-analysis and systematic
review. PLoS One. 11:e01521702016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Addeo R, Caraglia M, De Santi MS, Montella
L, Abbruzzese A, Parlato C, Vincenzi B, Carraturo M, Faiola V,
Genovese M, et al: A new schedule of fotemustine in
temozolomide-pretreated patients with relapsing glioblastoma. J
Neurooncol. 102:417–424. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Soffietti R, Trevisan E, Bosa C, Bertero L
and Ruda R: Phase II trial of bevacizumab and fotemustine in
recurrent grade III gliomas. J Clin Oncol. 30:Abstract 2075.
2012.
|
|
25
|
Vaccaro V, Fabi A, Vidiri A, Giannarelli
D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, et
al: Activity and safety of bevacizumab plus fotemustine for
recurrent malignant gliomas. BioMed Res Int. 2014:3512522014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soffietti R, Trevisan E, Bertero L,
Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione
A, Ciccone G, et al: Bevacizumab and fotemustine for recurrent
glioblastoma: A phase II study of AINO (Italian Association of
Neuro-Oncology). J Neurooncol. 116:533–541. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Z, Zhang G, Zhu L, Wang J, Liu D, Lian
L, Liu J, Lai T and Zhuang X: Retrospective analysis of bevacizumab
in combination with fotemustine in chinese patients with recurrent
glioblastoma multiforme. Biomed Res Int. 2015:7236122015.PubMed/NCBI
|
|
28
|
Archavlis E, Tselis N, Birn G, Ulrich P
and Zamboglou N: Salvage therapy for recurrent glioblastoma
multiforme: A multimodal approach combining fluorescence-guided
resurgery, interstitial irradiation, and chemotherapy. Neurol Res.
36:1047–1055. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Archavlis E, Tselis N, Birn G, Ulrich P
and Zamboglou N: Combined salvage therapies for recurrent
glioblastoma multiforme: Evaluation of an interdisciplinary
treatment algorithm. J Neurooncol. 119:387–395. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Scorsetti M, Navarria P, Pessina F,
Ascolese AM, D'Agostino G, Tomatis S, De Rose F, Villa E, Maggi G,
Simonelli M, et al: Multimodality therapy approaches, local and
systemic treatment, compared with chemotherapy alone in recurrent
glioblastoma. BMC Cancer. 15:4862015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wen PY, Macdonald DR, Reardon DA,
Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert
MR, Lassman AB, et al: Updated response assessment criteria for
high-grade gliomas: Response assessment in neuro-oncology working
group. J Clin Oncol. 28:1963–1972. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kaplan E and Meier P: Nonparametric
estimation from incomplete observations. J Am Stat Assoc.
53:457–481. 1958. View Article : Google Scholar
|
|
34
|
Common Terminology Criteria for Adverse
Events v4.03 (CTCAE). http://ctep.cancer.govJuly 22–2017
|
|
35
|
Mandl ES, Dirven CM, Buis DR, Postma TJ
and Vandertop WP: Repeated surgery for glioblastoma multiforme:
Only in combination with other salvage therapy. Surg Neurol.
69:506–509; discussion 509. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Straube C, Elpula G, Gempt J, Gerhardt J,
Bette S, Zimmer C, Schmidt-Graf F, Meyer B and Combs SE:
Re-irradiation after gross total resection of recurrent
glioblastoma: Spatial pattern of recurrence and a review of the
literature as a basis for target volume definition. Strahlenther
Onkol. 193:897–909. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cabrera AR, Kirkpatrick JP, Fiveash JB,
Shih HA, Koay EJ, Lutz S, Petit J, Chao ST, Brown PD, Vogelbaum M,
et al: Radiation therapy for glioblastoma: Executive summary of an
American Society for Radiation Oncology Evidence-Based Clinical
Practice Guideline. Pract Radiat Oncol. 6:217–225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Howard SP, Krauze A, Chan MD, Tsien C and
Tomé WA: The evolving role for re-irradiation in the management of
recurrent grade 4 glioma. J Neurooncol. 134:523–530. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Azoulay M, Santos F, Shenouda G, Petrecca
K, Oweida A, Guiot MC, Owen S, Panet-Raymond V, Souhami L and
Abdulkarim BS: Benefit of re-operation and salvage therapies for
recurrent glioblastoma multiforme: Results from a single
institution. J Neurooncol. 132:419–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
National Comprehensive Cancer Network:
NCCN Clinical Practice Guidelines in Oncology (NCCN
Guidelines®): Central Nervous System Cancers. NCCN
Evidence Blocks. Version 1.2017. https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdfDecember
5–2017
|
|
41
|
Lombardi G, Pambuku A, Bellu L, Farina M,
Della Puppa A, Denaro L and Zagonel V: Effectiveness of
antiangiogenic drugs in glioblastoma patients: A systematic review
and meta-analysis of randomized clinical trials. Crit Rev Oncol
Hematol. 111:94–102. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Taal W, Oosterkamp HM, Walenkamp AM,
Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D,
de Vos FY, et al: Single-agent bevacizumab or lomustine versus a
combination of bevacizumab plus lomustine in patients with
recurrent glioblastoma (BELOB trial): A randomised controlled phase
2 trial. Lancet Oncol. 15:943–953. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wick W, Brandes AA, Gorlia T, Bendszus M,
Sahm F, Taal W, Taphoorn M, Domont J, Idbaih A, Campone M, et al:
Phase III trial exploring the combination of bevacizumab and
lomustine in patients with first recurrence of a glioblastoma: The
EORTC 26101 trial. Neuro-oncol. 17 Suppl 5:LB052015. View Article : Google Scholar
|
|
44
|
Weathers SP, Han X, Liu DD, Conrad CA,
Gilbert MR, Loghin ME, O'Brien BJ, Penas-Prado M, Puduvalli VK,
Tremont-Lukats I, et al: A randomized phase II trial of standard
dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU)
in adults with recurrent glioblastoma. J Neurooncol. 129:487–494.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Heiland DH, Masalha W, Franco P, Machein
MR and Weyerbrock A: Progression-free and overall survival in
patients with recurrent Glioblastoma multiforme treated with
last-line bevacizumab versus bevacizumab/lomustine. J Neurooncol.
126:567–575. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Archavlis E: Combined Salvage Therapies
for Recurrent Glioblastoma Multiforme: Treatment Options in
Multifocal and Multicentric Patterns of Recurrence. J Cancer Prev
Curr Res. 7:002222017. View Article : Google Scholar
|
|
47
|
Piccioni DE, Selfridge J, Mody RR,
Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou
AP, et al: Deferred use of bevacizumab for recurrent glioblastoma
is not associated with diminished efficacy. Neuro-oncol.
16:815–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Weller M, Tabatabai G, Kästner B, Felsberg
J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC,
et al: DIRECTOR Study Group: MGMT promoter methylation is a strong
prognostic biomarker for benefit from dose-intensified temozolomide
rechallenge in progressive glioblastoma: The DIRECTOR Trial. Clin
Cancer Res. 21:2057–2064. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Szopa W, Burley TA, Kramer-Marek G and
Kaspera W: Diagnostic and Therapeutic Biomarkers in Glioblastoma:
Current Status and Future Perspectives. BioMed Res Int.
2017:80135752017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Brandes AA, Finocchiaro G, Zagonel V, Reni
M, Caserta C, Fabi A, Clavarezza M, Maiello E, Eoli M, Lombardi G,
et al: AVAREG: A phase II, randomized, noncomparative study of
fotemustine or bevacizumab for patients with recurrent
glioblastoma. Neuro-oncol. 18:1304–1312. 2016. View Article : Google Scholar : PubMed/NCBI
|
